

**FOR THE EXCLUSIVE USE OF TREYNOSO@KS-PROP.COM**

From the Boston Business Journal:

[http://www.bizjournals.com/boston/real\\_estate/2016/01/venture-backed-cambridge-biotech-moves-from.html](http://www.bizjournals.com/boston/real_estate/2016/01/venture-backed-cambridge-biotech-moves-from.html)

# Backed by \$77M in funding, Cambridge biotech moves from incubator to office

Jan 31, 2016, 8:14pm EST **Updated: Feb 1, 2016, 7:19am EST**

Cambridge-based immunotherapy company **Unum Therapeutics** has outgrown its Kendall Square incubator and moved headquarters to a former **Pfizer Inc.** (NYSE: PFE) property at 200 CambridgePark Drive.

Unum, which launched in late 2014 with \$12 million in funding, develops technology that aims to activate the body's own immune system to fight cancer. The company landed \$65 million in Series B funding in June, which was among the top venture capital deals in the commonwealth last year, according to Business Journal research.

The company has plans to grow to more than 80 employees this year and needed to grow beyond the LabCentral incubator program in Kendall Square. It has leased 33,000 square feet at 200 CambridgePark Drive, a facility located near the Alewife MBTA Red Line station that sold for \$165.5 million in late December.

"This move allows us to expand our hiring efforts within the world-class

Cambridge life sciences hub, to house a larger team of scientists, and to continue to leverage our proximity to leading research and academic institutions and healthcare companies," said Chuck Wilson, president and CEO of Unum Therapeutics, in a prepared statement. Unum is excited to be joining a growing biotech community in West Cambridge."

In the past 18 months, Cambridge-based life-science real estate firm King Street Properties redeveloped several properties along CambridgePark Drive, aiming to create what Principal Steve Lynch called a "Class A lab node in West Cambridge."

"When we bought and started our renovations to 200 CambridgePark Drive we were doing something at the very high end of the risk scale: making a market," Lynch said in a statement to the BBJ at the time of the 200 CambridgePark Drive sale. "By undertaking the repositioning of 200 CambridgePark Drive and two other nearby projects at the same time — 87 CambridgePark Drive and 733 Concord Ave. — we created a new Class A lab node in West Cambridge."

Since July 2014, eight buildings on CambridgePark Drive have sold for a combined \$447.6 million. For its part, 200 CambridgePark Drive was acquired by an entity called PFF OFF 200 CambridgePark Drive LLC for \$746 per square foot.

**Catherine Carlock**  
Real Estate Editor



WARREN PATTERSON  
87 & 200 Cambridge Park Drive  
(Cambridge): Building size: 288,891 square feet; sale price: \$54.5 million; price per square foot: \$189; sale date: June 23; Buyer: King Street Properties; Seller: Pfizer Inc.

## Boston Business Journal